Development and validation of an analytical method for the determination of related substances in bisoprolol fumarate in dosage forms by HPLC-UV-DAD
DOI:
https://doi.org/10.20450/mjcce.2021.2430Keywords:
bisoprolol, related substances, forced degradation studiesAbstract
The aim of this work was the development of an efficient analytical method for the determination of bisoprolol and related substances in the finished drug product using HPLC/DAD. Different bonded phases (alkyl and phenyl) with variable pore sizes and column dimensions, temperatures, and mobile phases with variable pH and additives were tested. Experiments that included using Hypersil 3 BDS C18 100 × 4 mm, 3 mm; Zorbax SB C18 150 × 4.6 mm, 3.5 mm; Acquity UPLC BEH C18 50 × 2.1 mm, 1.7 mm; and Xterra MS C18 100 × 4.6 mm, 3.5 mm gave the best results when considering the separation and resolution of the tested analytes within a reasonable run time. The method using Xterra MS C18 100 × 4.6 mm, 3.5 mm was validated as the most suitable when taking into account the mobile phase preparation and versatility, analysis time, and equipment maintenance.
Validation parameters (linearity, accuracy, precision, selectivity) confirmed the method as suitable for its intended use.
References
M. Szalka, J. Kostka, E. Rokaszewski, K. Kaczmarski, Analysis of related substances in bisoprolol fumarate on sub-2-μm adsorbents, Acta Chromatogr. 24(2), 63–183 (2012). DOI: https://doi.org/10.1556/achrom.24.2012.2.2.
D. J. Newman, Natural product-derived drugs based on β-adrenergic agents and nucleosides, J. Braz. Chem. Soc. 27(8), 1320–1333 (2016).
DOI: https://doi.org/10.5935/0103-5053.20160070.
European Pharmacopoeia, 8th edition, European Direc-torate for the Quality of Medicines and Healthcare, Coun-cil of Europe, Strasbourg, 2014. (Monograph for Bi-soprolol fumarate 01/2012:171 published on 1 January 2014).
British Pharmacopoeia, Stationary Office on Behalf of the Medicines and Healthcare Products Regulatory Agen-cy (MHRA), 2018. Monograph for Bisoprolol fumarate in British Pharmacopoeia published on 1 January 2018
T. Rakić, M. Jovanović, A. Tumpa, B. Jancić-Stojanović, M. Medenica, Optimizations of HILIC method for analy-sis of bisoprolol and its impurities considering uncertain-ties in peak positions, Arh. Farm. 64, 95–111 (2014). DOI: 10.5937/arhfarm1402095R.
I. Kasagić-Vujanović, B. Jancić Stojanović, D. Ivanović, Monitoring of bisoprolol fumarate stability under differ-ent stress conditions, IFMBE Proceedings 62 (2017). DOI: 10.1007/978-981-10-4166-2_64.
I. Mitrović, E. Kikovska-Stojanovska, G. Petrushevski, M. Chachorovska, S. Mehmed-Sejfulah, and S. Ugarkovic, Identification and structural characterization of unidentified impurity in bisoprolol film-coated tablets, Hindawi Advances in Chemistry 2017, 30475717 (2017). DOI: https://doi.org/10.1155/2017/3047517.
C. S. Mahu, F. A. Spac, C. Ciobanu, M. Hancianu, L. Agroroaei, E. Butnaru, Quantitative determination of bi-soprolol fumarate by HPLC, I. Method validation, Rev. Chim. 67(3), 414–417 (2016).
S. J. Joshi, P. A. Karbhari., S. I. Bhoir, K. S. Bindu, C. Das, RP-HPLC method for simultaneous estimation of bisoprolol fumarate and hydrochlorothiazide in tablet formulation, J. Pharm Biomed. Anal. 52(3), 362–71 (2010). DOI: 10.1016/j.jpba.2009.10.021.
I. Kasagić-Vujanović, B. Jancić Stojanović, T. Rakić, D. Ivanović, Design of experiments in optimization and vali-dation of a hydrophilic interaction liquid chromatography method for determination of amlodipine besylate and bi-soprolol fumarate, J. Liq. Chromatogr. Relat. Technol. 38(8), 919–928 (2015).
I. Kasagić-Vujanović, B. Jancić Stojanović, D. Ivanović, Forced degradation study of amlodipine besylate and bi-soprolol fumarate using chromatography with hydrophilic interactions, Arh. Farm. 64(3), 230–24 (2014). DOI: 10.5937/arhfarm1403230K.
ICH Guideline: Stability Testing of New Drug Substance and Product, ICH Q1A(R2), European Medical Agency, CPMP/ICH/2736/99, August 2003.
ICH Guideline: Photostability Testing of New Active Sub-stances and Medicinal Products, ICH Topic Q1B, Euro-pean Medical Agency, CPMP/ICH/279/95, January 1998.
A. H. Bakheit, A. Raisuddin, A. D. Alshahrania, and A. S. El-Azaba, Chapter Two – Bisoprolol: A comprehen-sive profile, Profiles of Drug Substances, Excipients, and Related Methodology, 46, 51–89 (2021).
DOI: 10.1016/bs.podrm.2020.07.006.
Y. Kazakevic, R. LoBrutto, HPLC for Pharmaceutical Scientists, John Wiley & Sons, 2007, pp. 139–239.
L. R. Snyder, J. J. Kirkland, J. W. Dolan, Introduction to Modern Liquid Chromatography, Third edition, John Wiley & Sons, 2010, pp. 404–470.
ICH Guideline: Validation of analytical procedures: Text and Methodology, ICH Q2(R1), European Medical Agency, CPMP/ICH/381/95, November 2005.
W. D. Reynolds, L. K. Facchine, F. J. Mullaney, K. M. Alsante, T. D. Hatajik, and M. G. Motto, Available guid-ance and best practices for conducting forced degradation studies, Pharm. Technol. 26, 48–56 (2002).
S. Krause, Analytical method development and optimiza-tion, BioPharm International, 2008 (2).
https://www.biopharminternational.com/view/analytical-method-development-and-optimization, accessed July 2021.
Pharmaceutical Technology Editors, Reconciling Mass Balance in Forced Degradation Studies, Pharmaceutical Technology, 29 (10).
https://www.pharmtech.com/view/reconciling-mass-balance-forced-degradation-studies, accessed July 2021.
Downloads
Published
How to Cite
Issue
Section
License
The authors agree to the following licence: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- for any purpose, even commercially.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
